With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

Among the 1000 patients with high-risk MDS, 32 (3%) had an IDH1 mutation, and among the 1300 patients with low-risk disease, 2.8% (n=37) had an IHD1 mutation.The prevalence of IDH1 mutations among ...

FIDH, OGDH and AVIPA are calling on the appeal judges to uphold the Guinean State’s obligation to ensure the payment of the sums awarded to the victims. The three NGOs are concerned about the ...

The current classification scheme uses molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct prognostic groups. Currently, neuroimaging followed by tissue biopsy ...

Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. The approval represents the first major treatment advance in low-grade brain cancer in more than ...

Mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) induce tumorigenesis due to generation of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). A hallmark of solid tumors carrying ...

There is a simple discount patient access scheme for ivosidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The first patient received their first dose on May 11, 2024. HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain ...

The first patient received their first dose on May 11, 2024. HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain ...

Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments. There is ...

The regulatory decision for the France-based drugmaker’s therapy, Tibsovo, covers the treatment of advanced cases of myelodysplastic syndromes characterized by an IDH1 mutation. Along with the ...